Retratrutide 20mg

Description

Retatrutide 20 mg is an investigational medication developed by Eli Lilly. It is designed as a once-weekly subcutaneous injection targeting three key receptors involved in metabolism:

• GLP-1 (Glucagon-Like Peptide-1): Enhances insulin secretion and suppresses appetite.

• GIP (Gastric Inhibitory Polypeptide): Improves insulin sensitivity.

• Glucagon: Increases energy expenditure and fat oxidation.

By activating these three pathways, Retatrutide aims to provide a comprehensive approach to managing obesity and type 2 diabetes.

Clinical Trial Results

In Phase 2 clinical trials, Retatrutide was administered in various dosages, including 1 mg, 4 mg, 8 mg, and 12 mg. The highest dose tested was 12 mg, which resulted in:

• Up to 24.2% mean body weight reduction over 48 weeks.

• Significant improvements in liver fat content, with reductions of up to 86% in participants with metabolic dysfunction-associated steatotic liver disease.

• Enhanced glucose control, with HbA1c reductions of up to 2.0% in participants with type 2 diabetes.

• A well-tolerated safety profile, with gastrointestinal side effects being the most common, primarily during dose escalation.

Dosage and Administration

• Formulation: Prefilled pen for once-weekly subcutaneous injection.

• Titration Schedule: Typically starts at 1 mg per week, with gradual increases to 2 mg, 4 mg, 8 mg, and up to 12 mg, depending on individual tolerance and response.

• Maintenance Dose: The optimal maintenance dose is still under investigation, with ongoing studies exploring the efficacy and safety of higher doses.

Potential Benefits

• Significant weight loss in individuals with obesity and type 2 diabetes.

• Improved glucose control and insulin sensitivity.

• Reduction in liver fat content, beneficial for individuals with non-alcoholic fatty liver disease (NAFLD).

• Enhanced energy expenditure due to glucagon receptor activation.

Retatrutide 20 mg Side Effects

• Gastrointestinal issues: Nausea, vomiting, and diarrhea, especially during dose escalation.

• Injection site reactions: Redness or swelling at the injection site.

• Headache and fatigue: Reported by some participants.

• No serious safety concerns were identified in the Phase 2 trials.